Defence Therapeutics Advances Strategic Initiatives with Key Appointments and Performance-Based Incentives
News related to:Defence Therapeutics Inc · 2 min read
Defence Therapeutics, a biotechnology company based in Montreal, Quebec, has announced a series of strategic moves aimed at advancing its Accum® precision drug delivery platform. Since Dr. Amie Phinney took the role of President and Chief Executive Officer in August, the company has been focused on executing its strategic priorities, as outlined in a recent shareholder letter.
Phinney, along with the Defence leadership team, has been working to translate the company’s strategy into actionable steps. Key initiatives include enhancing partnerships with Accum®-enhanced antibody-drug conjugate (ADC) programs, developing Accum®-enabled radiotherapeutics in-house, and evaluating strategic development options for AccuTOX®.
One significant move involves the appointment of Dr. Svetlana Selivanova to the Company’s Scientific Advisory Board (SAB). Selivanova, who previously served on the Board of Directors, will now contribute her expertise in radiopharmacology to support the company’s growing radiopharmaceutical program. This transition is part of Defence’s strategy to evaluate the potential of Accum® in improving the intracellular delivery and retention of radioisotopes in tumor cells.
In addition to these strategic appointments, Defence has also granted an aggregate of 7,000,000 incentive restricted stock units (RSUs) to key executives. These RSUs are structured as performance-based incentives tied to defined share-price milestones, aligning a significant portion of leadership compensation with long-term shareholder value creation.
Specifically, the RSUs will be issued in five equal installments upon the common shares of the company achieving closing prices on the Canadian Securities Exchange at or above $0.75, $1.00, $1.25, $1.50, and $1.75, respectively. Each RSU entitles the holder to receive one common share of the company. The RSUs expire on September 24, 2029, and remain subject to the terms of the company’s Omnibus Incentive Plan and applicable securities laws.
Defence has also provided an update on its Sharing Agreement with Sorbie Bornholm LP (SBLP), previously detailed in news releases from March 9 and February 27, 2026. As of September 15, 2026, the company has received a second settlement in the amount of $249,696.72, against 606,060 Placement Shares released to SBLP. Currently, 9,696,971 Placement Shares are held in escrow in connection with the Sharing Agreement, with 16 Settlement payments remaining.
The company remains focused on expanding opportunities to evaluate Accum® with partnered ADCs, generating foundational data, and advancing its Accum®-enabled radiotherapeutics programs. Defence expects to provide further updates as these initiatives progress.
The company’s commitment to making cancer treatment more effective and safer through its Accum® platform continues to drive its strategic initiatives. Defence Therapeutics is dedicated to bringing transformative therapies to patients in need.